Efficasy of Minodronic acid hydrate for the patients treated with Aromatase inhibitor

Efficasy of Minodronic acid hydrate for the patients treated with Aromatase inhibitor - Efficasy of Minodronic acid hydrate for the patients treated with AI

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008566

Enrollment

Registered

2012-10-01

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Medication of Minodronic acid hydrate Unmedication of Minodronic acid hydrate

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Postmenopausal breast cancer patients from 50 to 75 year old with boendensity <70%

Exclusion criteria

Exclusion criteria: Patients who cannot use Minodronic acid hydrate

Design outcomes

Primary

Measure	Time frame
bone density	—

Secondary

Measure	Time frame
bone metabolism	—

Countries

Japan

Contacts

Public ContactMichi Miki

The University of Tokushima graduate school Department of Thoracic, Endocrine surgery and Oncology

surgery2@clin.med.tokushima-u.ac.jp088-633-7143

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026